Published in Oncotarget on January 14, 2017
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 74.55
Cancer statistics, 2015. CA Cancer J Clin (2015) 57.51
IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 32.41
Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol (1990) 18.71
ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia (2004) 17.08
Genetic pathways to primary and secondary glioblastoma. Am J Pathol (2007) 9.27
The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol (2002) 8.62
Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci U S A (2005) 6.54
Rac activation and inactivation control plasticity of tumor cell movement. Cell (2008) 6.01
Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A. Cancer Cell (2011) 4.02
Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res (2004) 3.47
Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. Cell Stem Cell (2010) 3.34
Distinct roles of MLCK and ROCK in the regulation of membrane protrusions and focal adhesion dynamics during cell migration of fibroblasts. J Cell Biol (2004) 3.03
Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clin Cancer Res (2008) 2.52
Sildenafil use and increased risk of incident melanoma in US men: a prospective cohort study. JAMA Intern Med (2014) 2.50
Proneural transcription factors regulate different steps of cortical neuron migration through Rnd-mediated inhibition of RhoA signaling. Neuron (2011) 2.42
Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. BMC Med Genomics (2008) 2.29
A Rac-cGMP signaling pathway. Cell (2007) 2.16
Phosphodiesterases in the CNS: targets for drug development. Nat Rev Drug Discov (2006) 2.10
Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin Cancer Res (2003) 1.94
Smooth muscle phosphatase is regulated in vivo by exclusion of phosphorylation of threonine 696 of MYPT1 by phosphorylation of Serine 695 in response to cyclic nucleotides. J Biol Chem (2004) 1.81
Active Rho kinase (ROK-alpha ) associates with insulin receptor substrate-1 and inhibits insulin signaling in vascular smooth muscle cells. J Biol Chem (2001) 1.58
Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas. J Clin Oncol (2005) 1.46
KT5823 inhibits cGMP-dependent protein kinase activity in vitro but not in intact human platelets and rat mesangial cells. J Biol Chem (2000) 1.41
Rho GTPase signalling in cell migration. Curr Opin Cell Biol (2015) 1.38
cGMP-dependent protein kinase phosphorylates and inactivates RhoA. Biochem Biophys Res Commun (2001) 1.37
Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis. Cancer Res (2001) 1.29
Effects of two selective phosphodiesterase type 5 inhibitors, sildenafil and vardenafil, on object recognition memory and hippocampal cyclic GMP levels in the rat. Neuroscience (2002) 1.23
Soluble guanylyl cyclase: the nitric oxide receptor. Methods Enzymol (2005) 1.17
67-kDa laminin receptor increases cGMP to induce cancer-selective apoptosis. J Clin Invest (2013) 1.14
Beta catenin-independent activation of MyoD in presomitic mesoderm requires PKC and depends on Pax3 transcriptional activity. Dev Biol (2007) 1.11
PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor model. Brain Res (2008) 1.11
Nitric-oxide production by murine mammary adenocarcinoma cells promotes tumor-cell invasiveness. Int J Cancer (1999) 1.08
Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis. Cancer (2010) 1.07
Regulation of OSU-03012 toxicity by ER stress proteins and ER stress-inducing drugs. Mol Cancer Ther (2014) 1.05
Use of gel zymography to examine matrix metalloproteinase (gelatinase) expression in brain tissue or in primary glial cultures. Methods Mol Biol (2012) 1.03
Insidious role of nitric oxide in migration/invasion of colon cancer cells by upregulating MMP-2/9 via activation of cGMP-PKG-ERK signaling pathways. Clin Exp Metastasis (2012) 1.02
cGMP-Prkg1 signaling and Pde5 inhibition shelter cochlear hair cells and hearing function. Nat Med (2012) 0.99
Glial cell line-derived neutrotrophic factor and neurturin can act as paracrine growth factors stimulating DNA synthesis of Ret-expressing spermatogonia. Int J Oncol (2000) 0.97
Expression of EGFRvIII in glioblastoma: prognostic significance revisited. Neoplasia (2011) 0.97
Prognostic relevance of SOCS3 hypermethylation in patients with glioblastoma multiforme. Int J Cancer (2008) 0.96
Human PDE5A gene encodes three PDE5 isoforms from two alternate promoters. Int J Impot Res (2002) 0.95
Expression, structure and chromosomal localization of the human cGMP-binding cGMP-specific phosphodiesterase PDE5A gene. Eur J Biochem (1998) 0.94
Molecular properties of mammalian proteins that interact with cGMP: protein kinases, cation channels, phosphodiesterases, and multi-drug anion transporters. Front Biosci (2005) 0.92
PDE5 inhibitors enhance the lethality of standard of care chemotherapy in pediatric CNS tumor cells. Cancer Biol Ther (2014) 0.92
Central Nervous System Cancers, Version 1.2015. J Natl Compr Canc Netw (2015) 0.90
cGMP-dependent protein kinase Iβ regulates breast cancer cell migration and invasion via interaction with the actin/myosin-associated protein caldesmon. J Cell Sci (2013) 0.88
Epigenetic silencing of Id4 identifies a glioblastoma subgroup with a better prognosis as a consequence of an inhibition of angiogenesis. Cancer (2012) 0.86
Subcellular localization and regulation of type-1C and type-5 phosphodiesterases. Biochem Biophys Res Commun (2006) 0.86
Cyclic GMP regulation of myosin phosphatase: a new piece for the puzzle? Circ Res (2007) 0.86
Phosphodiesterase type 5 inhibitors increase Herceptin transport and treatment efficacy in mouse metastatic brain tumor models. PLoS One (2010) 0.86
KAP regulates ROCK2 and Cdk2 in an RNA-activated glioblastoma invasion pathway. Oncogene (2014) 0.86
Function and regulation of Rnd proteins in cortical projection neuron migration. Front Neurosci (2015) 0.85
Expression and Function of Phosphodiesterase Type 5 in Human Breast Cancer Cell Lines and Tissues: Implications for Targeted Therapy. Clin Cancer Res (2015) 0.84
Sildenafil Potentiates a cGMP-Dependent Pathway to Promote Melanoma Growth. Cell Rep (2016) 0.83
Soluble guanylate cyclase generation of cGMP regulates migration of MGE neurons. J Neurosci (2013) 0.78
Stimulation of neural stem cell proliferation by inhibition of phosphodiesterase 5. Stem Cells Int (2014) 0.78
Tumorigenesis: the origins of glioma. Nat Rev Cancer (2011) 0.77
Platelet-derived growth factor regulation of type-5 phosphodiesterase in human and rat penile smooth muscle cells. J Sex Med (2014) 0.77
Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clin Cancer Res (2008) 2.52
Phenotypic characterization of human prostatic stromal cells in primary cultures derived from human tissue samples. Int J Oncol (2013) 0.79
Evaluation of the efficacy and safety of Tribulus terrestris in male sexual dysfunction-A prospective, randomized, double-blind, placebo-controlled clinical trial. Maturitas (2017) 0.76
Adjuvant radiation therapy in stage I seminoma: 20 years of oncologic results. Oncotarget (2016) 0.75
Antitumor activity of a novel anti-vascular endothelial growth factor receptor-1 monoclonal antibody that does not interfere with ligand binding. Oncotarget (2016) 0.75
Erratum to: KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models. BMC Cancer (2016) 0.75
EGFR heterogeneity and implications for therapeutic intervention in glioblastoma. Neuro Oncol (2017) 0.75
Modulation of GDF11 expression and synaptic plasticity by age and training. Oncotarget (2017) 0.75
High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts in vitro. Oncotarget (2017) 0.75
Platelet-derived growth factor-C promotes human melanoma aggressiveness through activation of neuropilin-1. Oncotarget (2017) 0.75
Platelet-derived growth factor-C promotes human melanoma aggressiveness through activation of neuropilin-1. Oncotarget (2017) 0.75